Nimbus Discovery is applying advances in computer-based drug discovery to unlock fundamental biological pathways. Nimbus has already delivered selective, potent, and differentiated compounds for two disease targets, IRAK4 and ACC, which are pivotal to the progression of an aggressive subtype of non-Hodgkin’s lymphoma and metabolic disease, respectively. Nimbus has identified drug candidates for these targets and has expanded its pipeline to include additional important programs.
Nimbus receives privileged access to leading-edge technology, including next-generation WaterMapTM, Free Energy Perturbation (FEP), Molecular Dynamics software, as well as exclusive rights to key targets. Under the terms of the agreement established in 2010, Nimbus receives exclusive use of customized software packages developed by Schrödinger for these targets, access to a dedicated team of Schrödinger computational chemists and unlimited use of cloud computing resources. In the context of this unique partnership, Nimbus maintains a continuous and sustainable first-mover advantage that can be applied across multiple targets classes and types of chemistry problem.
To maximize scalability and flexibility, Nimbus leverages a small and highly experienced internal team across a network of external R&D partners. This is achieved through milestone-based agreements and flexible collaborations, now implemented with top-tier chemistry, crystallography, fragment-based discovery and specialized pharmacology providers. At steady state, Nimbus anticipates having ~10x more FTEs working outside versus inside the company while targeting low fixed costs. In addition, Nimbus partners with academic collaborators at leading research institutions to access cutting-edge disease biology capabilities.
Each Nimbus program is placed in its own dedicated subsidiary under an LLC umbrella providing deal flexibility without foregoing any of the traditional benefits of C-corps. This enables project-driven transactions with Pharma allowing partners to finance target-specific subsidiaries and own the IP/assets of a particular program. For investors, this approach solves the classic drug discovery illiquidity problem where it takes 7-10 years to get a return on capital via M&A or an IPO. The LLC structure enables shareholders to cycle capital back to investors in a tax-efficient manner on a per project basis.